Results 81 to 90 of about 30,994 (308)

The first generic tirzepatide GP30931: physicochemical and biological similarity to the reference drug

Разработка и регистрация лекарственных средств
Introduction. Metabolic syndrome is a multifactorial complex of metabolic disorders accompanied by type 2 diabetes mellitus and abdominal obesity.
I. A. Lugovik, A. V. Babina, S. S. Arutyunyan, D. О. Ermolaeva, V. B. Saparova, T. N. Kobeleva, P. G. Zaikin, A. D. Mikushina, A. S. Bukatin, I. E. Eliseev, B. Ts. Zajchik, Y. S. Keruchenko, I. S. Ohrimenko, E. V. Bocharov, A. Kh. Taldaev, V. A. Lushpa, I. E. Makarenko, R. V. Drai   +17 more
doaj   +1 more source

The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson’s Disease

Journal of Parkinson's Disease, 2020
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disease for which there is no cure. In a clinical trial, the glucagon-like peptide-1 (GLP-1) receptor agonist exendin-4 has shown good protective effects in PD patients.
Lingyu Zhang, Liping Zhang, Yanwei Li, Lin Li, Josefine U Melchiorsen, M. Rosenkilde, C. Hölscher   +6 more
semanticscholar   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

Vaccination against GIP for the treatment of obesity. [PDF]

PLoS ONE, 2008
BACKGROUND: According to the WHO, more than 1 billion people worldwide are overweight and at risk of developing chronic illnesses, including cardiovascular disease, type 2 diabetes, hypertension and stroke. Current therapies show limited efficacy and are
Alma Fulurija, Thomas A Lutz, Katja Sladko, Melania Osto, Peter Y Wielinga, Martin F Bachmann, Philippe Saudan   +6 more
doaj   +1 more source

GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance

Chronic Diseases and Translational Medicine, EarlyView.
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig, Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Frances Osler, Marije Jansen, Puneet Chhabra   +7 more
wiley   +1 more source

GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Disease–A Systematic Review

International Journal of Molecular Sciences, 2020
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are gut hormones that are secreted from enteroendocrine L cells and K cells in response to digested nutrients, respectively.
Y. Mori, T. Matsui, T. Hirano, S. Yamagishi   +3 more
semanticscholar   +1 more source

Peptide Marriages: Modular Assembly of Multi‐Agonist Therapeutics

Chemistry – A European Journal, EarlyView.
A modular polyethylene glycol (PEG) scaffold enables rapid assembly of dual peptide agonists using strain‐promoted azide–alkyne cycloaddition (SPAAC) and copper‐catalysed azide–alkyne cycloaddition (CuAAC). Glucagon‐like peptide‐1 (GLP‐1) and amylin agonists were combined with controlled valency, yielding low‐picomolar activity and receptor‐selective ...
Kristina A. Kostadinova, Jan L. Venne, Sona Krajcovicova, James Dodgson, Wouter F. J. Hogendorf, Thomas E. Nielsen, David Hymel, Hannah Bolt, Andie Collinson, Jason Day, Jefferson Revell, David R. Spring   +11 more
wiley   +1 more source

Serum and expression profiles of glucose-dependent insulinotropic polypeptide in correlation with cardiometabolic risk factors among patients with systemic lupus erythematosus

The Egyptian Journal of Internal Medicine, 2019
Background Premature atherosclerosis has been recognized as a major co-morbid condition in systemic lupus erythematosus (SLE). Glucose-dependent insulinotropic polypeptide (GIP) is closely related to cardiovascular (CV) risk factors. We aimed to evaluate
Nearmeen M Rashad, Reem M Allam, Amany M Ebaid, Mohammed S Yousef, Maha A Fathy   +4 more
doaj   +1 more source

Alterations of glucose-dependent insulinotropic polypeptide and expression of genes involved in mammary gland and adipose tissue lipid metabolism during pregnancy and lactation. [PDF]

PLoS ONE, 2013
Gastric inhibitory polypeptide (GIP) is a gut derived peptide with multiple emerging physiological actions. Effects of pregnancy and lactation on GIP secretion and related gene expression were studied in Wistar rats.
R Charlotte Moffett, Nigel Irwin, Jacqueline M E Francis, Peter R Flatt   +3 more
doaj   +1 more source

The incretin system in healthy humans: The role of GIP and GLP-1.

Metabolism: Clinical and Experimental, 2019
The incretin effect, the amplification of insulin secretion occurring when glucose is taken in orally as compared to infused intravenously, is one of the factors that help the body to tolerate carbohydrate/glucose ingestion.
J. Holst
semanticscholar   +1 more source